Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PTrana Meditama Metropolitan Tbk's quarterly other current liabilities
declined
from Dec. 2025 (Rp106,663 Mil) to Mar. 2026 (Rp81,107 Mil) and
declined
from Mar. 2026 (Rp81,107 Mil) to Jun. 2026 (Rp79,965 Mil).
PTrana Meditama Metropolitan Tbk's annual other current liabilities
increased
from Dec. 2023 (Rp93,252 Mil) to Dec. 2024 (Rp96,741 Mil) and
increased
from Dec. 2024 (Rp96,741 Mil) to Dec. 2025 (Rp106,663 Mil).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PTrana Meditama Metropolitan Tbk Other Current Liabilities Chart
PTrana Meditama Metropolitan Tbk Other Current Liabilities Calculation
The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.
What does a Other Current Liabilities of Rp79,965 Mil mean?
PTrana Meditama Metropolitan Tbk (ISX:SAME) has a Other Current Liabilities of Rp79,965 Mil as of Jun. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on PTrana Meditama Metropolitan Tbk.
Is PTrana Meditama Metropolitan Tbk's Other Current Liabilities too high?
PTrana Meditama Metropolitan Tbk's current Other Current Liabilities is Rp79,965 Mil. Overall, PTrana Meditama Metropolitan Tbk has a GF Score™ of 65/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PTrana Meditama Metropolitan Tbk's Other Current Liabilities compare to HCA and THC?
PTrana Meditama Metropolitan Tbk's Other Current Liabilities of Rp79,965 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Healthcare Providers & Services company?
A good Other Current Liabilities depends on the Healthcare Providers & Services industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on PTrana Meditama Metropolitan Tbk. PTrana Meditama Metropolitan Tbk's current Other Current Liabilities is Rp79,965 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PTrana Meditama Metropolitan Tbk stock overvalued right now?
Based on GuruFocus' analysis, PTrana Meditama Metropolitan Tbk (ISX:SAME) is currently considered Modestly Undervalued. The stock's GF Value™ is Rp354.65, compared to a current price of Rp320.00 — trading 9.8% below its estimated fair value. The current Other Current Liabilities is Rp79,965 Mil. PTrana Meditama Metropolitan Tbk's overall GF Score™ is 65/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For PTrana Meditama Metropolitan Tbk (ISX:SAME), the current Other Current Liabilities is Rp79,965 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PTrana Meditama Metropolitan Tbk (ISX:SAME) Overvalued in 2026?
Based on GuruFocus' analysis, PTrana Meditama Metropolitan Tbk stock appears to be undervalued.
The current stock price of Rp320.00 is trading 9.8% below its estimated GF Value™ of Rp354.65.
GuruFocus considers PTrana Meditama Metropolitan Tbk to be Modestly Undervalued.
Key valuation signals for ISX:SAME:
Other Current Liabilities: Rp79,965 Mil
GF Value™: Rp354.65 vs. price of Rp320.00 (9.8% below fair value)
No single metric tells the full story. See the ISX:SAME stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Sarana Meditama Metropolitan Tbk is engaged in managing hospitals. Its hospitals are operated under the brand name Omni Hospital. The company manages and evaluates its business based on its geographic location consisting of Omni Pulomas, Omni Alam Sutera, Omni Cikarang, OMNI Pekayon, and others. It operates in Banten, DKI Jakarta, and West Java.
65GF Score
Get the complete analysis for ISX:SAME
Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:SAME has been successfully added to your 
